Trastuzumab deruxtecan in the treatment of breast cancer

V.F. Semiglazov, P.V. Krivorotko, N.B. Bekkeldieva, A.O. Gorina, A.V. Komyakhov, R.M. Paltuev, T.T. Tabagua, S.S. Ereshenko

N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia

HER2-positive breast cancer (BC), defined by HER2 gene amplification and/or overexpression at the protein level, accounts for approximately 20% of all BC cases. The use of the anti-HER2 drug trastuzumab, developed 20 years ago, changed the natural course of the disease and improved the clinical outcome. Subsequent use of “dual blockade” (trastuzumab-pertuzumab; trastuzumab-lapatinib), as well as an antibody-drug conjugate (T-DM1), improved relapse-free and overall survival of patients with HER2-positive BC. Further progress in anti-HER2 targeted therapy is associated with the use of a new generation of conjugates – trastuzumab-deruxtecan (T-Dxd). In addition, a number of clinical trials on the successful use of T-Dxd in patients with lower HER2 protein expression (HER2 1+ or 2+ with negative in situ hybridization (ISH-) levels, detected in half of BC patients have been performed.

Keywords

About the Authors

Corresponding author: Vladimir F. Semiglazov, Dr. Sci. (Med.), Professor, Corresponding Member of  RAS, Oncologist, Head of the Scientific Department of Tumors of the Reproductive System, Chief Researcher at the Petrov National Medical Research Center of Oncology, St. Petersburg, Russia; vsemiglazov@mail.ru

Similar Articles